Jim Scopa has more than 30 years of experience in the life sciences industry, investing in companies and advising public and private boards on strategic and financial transactions. From 2005 to 2017 he served as a managing director and a member of the investment committee of MPM Capital, a global life sciences venture capital firm. Prior to MPM, Mr. Scopa spent 18 years advising growth companies in biopharmaceuticals and medical devices principally at Deutsche Banc Alex. Brown and Thomas Weisel Partners. Mr. Scopa currently serves on the boards of Adverum Biotechnologies, Aligos Therapeutics, Blade Therapeutics and Neuron23, Inc., as well as on the investment committee of One Ventures. He previously served on the boards of Semma Therapeutics (sold to Vertex), True North Therapeutics (sold to BioVerativ) and iPierian (sold to Bristol Myers Squibb). In 2017, he was appointed a fellow in the Distinguished Careers Institute at Stanford.
Mr. Scopa received an A.B. from Harvard College, an MBA from Harvard Business School and a J.D. from Harvard Law School.